A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 34
Summary
- Conditions
- Leukemia
- Lymphoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: This is an open-label multicenter, single-arm, phase II trial of CPI-613 monotherapy.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03793140
- Collaborators
- City of Hope Medical Center
- Massachusetts General Hospital
- M.D. Anderson Cancer Center
- George Washington University
- Investigators
- Principal Investigator: Ariela Noy, MD Memorial Sloan Kettering Cancer Center
Get Well Soon